Login to Your Account



Therion Starting Panvac-VF Phase III Under SPA Program

By Aaron Lorenzo


Monday, May 24, 2004
Therion Biologics Corp. is moving its lead vaccine candidate into Phase III work. The Cambridge, Mass.-based company plans to begin this summer a trial evaluating Panvac-VF in metastatic pancreatic cancer patients who have failed treatment with gemcitabine. The FDA signed off on the study, which will be conducted under the agency's special protocol assessment (SPA) program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription